semaglutide alzheimer's phase 3 GLP-1 receptor agonist fails to halt Alzheimer's disease

evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia

20.57

★★★★☆4.8 (126)

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

21.44

★★★★★4.9 (98)

Live Updates on Semaglutide's Current and Future Uses

20.06

★★★★★5.0 (157)

Semaglutide (Ozempic) did not slow Alzheimer's disease progression in phase 3 EVOKE/EVOKE+ trials of adults 55–85 with MCI or early dementia due to AD

26.20

★★★★★4.7 (84)

The evoke and evoke+ Phase 3 trials found that oral semaglutide was not superior to placebo in reducing the progression of Alzheimer's disease in patients with early-stage symptomatic disease, leading to the

28.54

★★★★★4.9 (203)

Alzheimer's disease: Semaglutide use linked to lower risk

22.77

★★★★★5.0 (176)

Weight-loss drug semaglutide does not slow Alzheimer's disease, two clinical trials find

21.72

★★★★★4.8 (132)